Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma

References

• Barlogie B, Epstein J. Multiple myeloma: biology and therapy. J Cancer Res Clin Oncol 1990;116(1):109–11. doi: 10.1007/BF01612651
   PubMed Web of Science ®Google Scholar
• Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res 2011;183:25–35. doi: 10.1007/978-3-540-85772-3_2
   PubMedGoogle Scholar
• Kuku I, Aydogdu I, Bayraktar N, Kaya E, Akyol O, Erkurt MA. Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma. Cell Biochem Funct 2005;23(1):47–50. doi: 10.1002/cbf.1127
   PubMed Web of Science ®Google Scholar
• Gerber M, Astre C, Segala C, Saintot M, Scali J, Simony-Lafontaine J, et al. Oxidant-antioxidant status alterations in cancer patients: relationship to tumor progression. J Nutr 1996;126(4):1201S–7S.
   PubMed Web of Science ®Google Scholar
• Sosa V, Moline T, Somoza R, Paciucci R, Kondoh H, Lleonart ME. Oxidative stress and cancer: an overview. Ageing Res Rev 2012;12(1):37.90–6.
   Google Scholar
• Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts II, LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87(23):9383–7. doi: 10.1073/pnas.87.23.9383
   PubMed Web of Science ®Google Scholar
• Barrera G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol 2012;2012:137289.
   PubMedGoogle Scholar
• Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7(2):69–76. doi: 10.1097/00041433-199604000-00004
   PubMed Web of Science ®Google Scholar
• Akcay MN, Yilmaz I, Polat MF, Akcay G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003;50(2):cclxxiii–cclxxv.
   PubMedGoogle Scholar
• Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;7:48. doi: 10.1186/1471-2407-7-48
   PubMed Web of Science ®Google Scholar
• Krzystek-Korpacka M, Boehm D, Matusiewicz M, Diakowska D, Grabowski K, Gamian A. Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes – connection with inflammation. Clin Biochem 2008;41(10–11):804–11. doi: 10.1016/j.clinbiochem.2008.03.012
   PubMed Web of Science ®Google Scholar
• Stevens VL, Rodriguez C, Pavluck AL, Thun MJ, Calle EE. Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2006;15(6):1226–8. doi: 10.1158/1055-9965.EPI-05-0930
   PubMed Web of Science ®Google Scholar
• Balci H, Genc H, Papila C, Can G, Papila B, Yanardag H, et al. Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer. J Clin Lab Anal 2012;26(3):155–60. doi: 10.1002/jcla.21503
   PubMed Web of Science ®Google Scholar
• Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer 2008;95(3):301–13.
   PubMed Web of Science ®Google Scholar
• Taverne YJ, Bogers AJ, Duncker DJ, Merkus D. Reactive oxygen species and the cardiovascular system. Oxid Med Cell Longev 2013;2013:862423. doi: 10.1155/2013/862423
   PubMed Web of Science ®Google Scholar
• Stojnev S, Ristic-Petrovic A, Jankovic-Velickovic L. Reactive oxygen species, apoptosis and cancer. Vojnosanit Pregl 2013;70(7):675–8. doi: 10.2298/VSP1307675S
   PubMed Web of Science ®Google Scholar
• Martins Chaves M, Rocha-Vieira E, Pereira dos Reis A, de Lima e Silva R, Gerzstein NC, Nogueira-Machado JA. Increase of reactive oxygen (ROS) and nitrogen (RNS) species generated by phagocyting granulocytes related to age. Mech Ageing Dev 2000;119(1–2):1–8. doi: 10.1016/S0047-6374(00)00153-6
   PubMed Web of Science ®Google Scholar
• Montuschi P, Barnes PJ, Roberts 2nd, LJ. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18(15):1791–800. doi: 10.1096/fj.04-2330rev
   PubMed Web of Science ®Google Scholar
• Khadem-Ansari MH, Shahsavari Z, Rasmi Y, Mahmoodlo R. Elevated levels of urinary 8-hydroxy-2′-deoxyguanosine and 8-isoprostane in esophageal squamous cell carcinoma. J Carcinog 2011;10:14. doi: 10.4103/1477-3163.79683
   PubMedGoogle Scholar
• Dalaveris E, Kerenidi T, Katsabeki-Katsafli A, Kiropoulos T, Tanou K, Gourgoulianis KI, et al. VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer 2009;64(2):225–19. doi: 10.1016/j.lungcan.2008.08.015
   Web of Science ®Google Scholar
• Zima T, Spicka I, Stipek S, Crkovska J, Platenik J, Merta M, et al. Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma. Neoplasma 1996;43(2):69–73.
   PubMed Web of Science ®Google Scholar
• Sharma A, Tripathi M, Satyam A, Kumar L. Study of antioxidant levels in patients with multiple myeloma. Leuk Lymph 2009;50(5):809–15. doi: 10.1080/10428190902802323
   PubMed Web of Science ®Google Scholar
• Lodh M, Goswami B, Gupta N, Patra SK, Saxena A. Assessment of oxidative stress and inflammatory process in patients of multiple myeloma. Indian J Clin Biochem 2012;27(4):410–3. doi: 10.1007/s12291-012-0222-y
   PubMedGoogle Scholar
• Gangemi S, Allegra A, Alonci A, Cristani M, Russo S, Speciale A, et al. Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflamm Res 2012;61(10):1063.7. doi: 10.1007/s00011-012-0498-7
   Google Scholar
• Ellidag HY, Eren E, Aydin O, Yildirim M, Sezer C, Yilmaz N. Multiple myeloma: relationship to antioxidant esterases. Med Princ Pract 2014;23(1):18–23. doi: 10.1159/000355826
   PubMed Web of Science ®Google Scholar
• Sehitogullari A, Aslan M, Sayir F, Kahraman A, Demir H. Serum paraoxonase-1 enzyme activities and oxidative stress levels in patients with esophageal squamous cell carcinoma. Redox Rep 2014;19(5):199–205. doi: 10.1179/1351000214Y.0000000091
   PubMed Web of Science ®Google Scholar
• Akcay MN, Polat MF, Yilmaz I, Akcay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003;50(2):ccxxv–ii.
   PubMedGoogle Scholar
• Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, et al. Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med 2000;6(3):307–11.
   PubMed Web of Science ®Google Scholar
• von Meyenfeldt M. Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs 2005;9(2):S35–8. doi: 10.1016/j.ejon.2005.09.001
   Google Scholar
• Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997;11(6):457–65.
   PubMed Web of Science ®Google Scholar